Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT07741123
Starting soon Not applicable

HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea

NCT07741123 · tracked via the Priya Life Science South Korea tracker
Sponsor
Seul Ki Choi
Phase
Not applicable
Started
2026-09-01
Last updated
2026-08-03

Condition(s) studied

HIV InfectionsHIV Prevention and CareRisk Reduction BehaviorDigital Health

Investigational drug(s) / intervention(s)

Bandi Mobile Application (Full Access)Information-Only Mobile Application (Limited Access)

Bandi Mobile Application (Full Access): A culturally adapted digital HIV prevention mobile application designed for young men who have sex with men (MSM) in South Korea. Participants receive 3-month access to five core integrated features: interactive health articles and quizzes (covering PrEP, adherence, and sexual health); moderated peer community discussion forums and polls; Love Log (a sexual health tracking and planning tool); Care Locator (a directory of local HIV/STI testing centers); and gamification elements (customizable avatars and badges).

Information-Only Mobile Application (Limited Access): A limited version of the mobile application provided to the control group over a 3-month period. Access is restricted to static online educational articles/resources and the Care Locator feature for finding local HIV/STI testing centers.

Study summary

This study tests a mobile application (app) designed to support sexual health and prevent human immunodeficiency virus (HIV) among young men in South Korea. Researchers are interested to learn if the app is acceptable, easy to use, and helpful for young men who have sex with men (MSM).

Participants will complete a 15-minute online survey at the start of the study and another 15-minute survey 3 months later. Participants will be randomly assigned to 1 of 2 study groups for 3 months:

1. Intervention Group: Participants receive access to the full mobile app, called Bandi. The app includes health articles, quizzes, community discussion forums, a personal sexual health log, and a clinic finder.
2. Control Group: Participants receive access to a basic version of the app that includes informational articles and the clinic finder only.

Researchers will compare both groups over 3 months to see if using the full app leads to higher rates of HIV testing and lower sexual risk behaviors.

Eligibility

Sex
MALE
Min age
18 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Male sex assigned at birth and current male gender identity * Aged 18 to 35 years * Current residence in the Seoul Metropolitan area * Korean nationality * Self-identify as a sexual minority (e.g., gay, bisexual, queer, or other non-heterosexual identity) * HIV-negative or HIV-unaware serostatus * Report at least 1 episode of condomless anal intercourse with a male partner in the prior 6 months Exclusion Criteria: * Assigned female at birth or do not currently identify as male * Younger than 18 or older than 35 years of age * Non-residence in the Seoul Metropolitan area * Do not hold Korean nationality * Do not identify as a sexual minority * Known HIV-positive status * No reported episodes of condomless anal intercourse with a male partner in the prior 6 months

Primary outcome measure(s)

  • Proportion of Participants Who Reported Receiving an HIV Test — 3 months post-randomization
    Self-reported status of receiving an HIV test (Yes/No) as assessed via a web-based survey.
  • Change in Frequency of Condomless Anal Intercourse (CAI) — Baseline and 3 months post-randomization
    Self-reported number of condomless anal intercourse episodes with male partners in the prior 3 months, assessed via web-based survey.

Trial sites (1)

FacilityCityRegionStatus
Ewha Womans University Seoul South Korea

Other trials for the same condition

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults Active, not recruiting
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults Active, not recruiting
Development and Validation of a Personalized Digital Healthcare Model for Managing Side Effects in Breast Cancer Survivors Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07741123 on ClinicalTrials.gov ↗ ← All trials in South Korea